.jpg)
Last Updated: Thursday, 17-Oct-2019 16:30:00 EDT
NLA Scientific Statement on the Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk
NLA Scientific Statement on the Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk
Carl E. Orringer, MD, FNLA; Terry A. Jacobson, MD, FNLA; Kevin C. Maki, PhD, FNLA
Highlights:
- Hypertriglyceridemia is associated with increased ASCVD risk
- Long chain omega-3 fatty acids lower circulating TG
- Benefits of low dose omega-3 have been controversial
- In REDUCE-IT icosapent ethyl demonstrated 25% net ASCVD risk reduction
- NLA: Use icosapent ethyl in selected high TG ASCVD &/or diabetic patients on statin
Read Full Statement
Resources
Podcast activity is not offered for CME/CE credit.